Literature DB >> 3079540

Plasma lipoprotein changes in humans induced by beta-interferon.

I B Rosenzweig1, D A Wiebe, E C Borden, B Storer, E S Shrago.   

Abstract

Two groups of patients were administered either 4.5 X 10(6) U or 90 X 10(6) U each of recombinant DNA-derived interferon-beta serine (IFN-beta ser) i.v. daily for 10 days. IFN-beta ser affected lipoprotein lipids of patients in a dose dependent fashion. A decrease in plasma total cholesterol concentration occurred 24 h after therapy was initiated, regardless of dose. A dose-related decrease in plasma cholesterol concentration of 9% and 23% for patients on the low dose and high dose respectively occurred after 9 days of therapy. The plasma total cholesterol concentration decrease resulted primarily from a decrease in LDL cholesterol of 28% and 50% for patients on low and high doses respectively of IFN-beta ser. HDL-cholesterol was not significantly affected by IFN-beta ser administration. A dose-related increase in plasma triglyceride concentration occurred during IFN-beta ser, increasing 74% for patients on low dose and 136% for patients on high doses. This increase was only observed after 9 days on IFN-beta ser. Cholesterol reduction and triglyceride increases followed different time courses indicating different mechanisms may be involved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3079540     DOI: 10.1016/0021-9150(87)90287-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

2.  Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease.

Authors:  S M Jones; C P Harris; J Lloyd; C A Stirling; J P Reckless; N J McHugh
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 4.  Infection homeostasis: implications for therapeutic and immune programming of metabolism in controlling infection.

Authors:  Konstantinos Kotzamanis; Ana Angulo; Peter Ghazal
Journal:  Med Microbiol Immunol       Date:  2015-03-24       Impact factor: 3.402

5.  The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.

Authors:  Hee Jae Jung; Young Seok Kim; Sang Gyune Kim; Yun Nah Lee; Soung Won Jeong; Jae Young Jang; Sae Hwan Lee; Hong Soo Kim; Boo Sung Kim
Journal:  Clin Mol Hepatol       Date:  2014-03-26

6.  Cholesterol levels and long-term rates of community-acquired sepsis.

Authors:  Faheem W Guirgis; John P Donnelly; Sunita Dodani; George Howard; Monika M Safford; Emily B Levitan; Henry E Wang
Journal:  Crit Care       Date:  2016-12-23       Impact factor: 9.097

Review 7.  Interferon Control of the Sterol Metabolic Network: Bidirectional Molecular Circuitry-Mediating Host Protection.

Authors:  Kevin A Robertson; Peter Ghazal
Journal:  Front Immunol       Date:  2016-12-23       Impact factor: 7.561

8.  Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.

Authors:  Kirsty E Waddington; Artemis Papadaki; Leda Coelewij; Marsilio Adriani; Petra Nytrova; Eva Kubala Havrdova; Anna Fogdell-Hahn; Rachel Farrell; Pierre Dönnes; Inés Pineda-Torra; Elizabeth C Jury
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.